481 related articles for article (PubMed ID: 12018108)
1. Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic or unresectable localized non-small-cell lung cancer.
Kim YH; Kim JS; Choi YH; In KH; Park HS; Hong DS; Jeong TJ; Lee YY; Nam E; Lee SN; Lee KS; Kim HK
Int J Clin Oncol; 2002 Apr; 7(2):114-9. PubMed ID: 12018108
[TBL] [Abstract][Full Text] [Related]
2. Phase II study with fractionated schedule of docetaxel and cisplatin in patients with advanced non-small cell lung cancer.
Kwon JH; Kim JH; Lee JA; Shin HC; Kim HJ; Song HH; Jung JY; Kim HY; Choi DR; Kim HS; Park YI; Zang DY
Cancer Chemother Pharmacol; 2010 Oct; 66(5):889-97. PubMed ID: 20091311
[TBL] [Abstract][Full Text] [Related]
3. A multicenter phase II study of docetaxel and carboplatin combination as front-line treatment in advanced non-small cell lung cancer.
Giannakakis T; Kakolyris S; Theodoropoulos E; Kouroussis C; Michailakis E; Papadouris S; Tsitoura M; Kalbakis K; Souglakos J; Agelaki S; Vardakis N; Georgoulias V
Anticancer Res; 2002; 22(6B):3743-8. PubMed ID: 12552987
[TBL] [Abstract][Full Text] [Related]
4. First-line treatment of advanced nonsmall cell lung carcinoma with docetaxel and vinorelbine.
Kourousis C; Androulakis N; Kakolyris S; Souglakos J; Maltezakis G; Metaxaris G; Chalkiadakis G; Samonis G; Vlachonikolis J; Georgoulias V
Cancer; 1998 Nov; 83(10):2083-90. PubMed ID: 9827712
[TBL] [Abstract][Full Text] [Related]
5. Outcome of metastatic non-small cell lung carcinoma patients receiving docetaxelcisplatin combination chemotherapy: single institution experience.
Kocak M; Mayadagli A; Ozkan A; Parlak C; Demir O; Marti A; Dogan Eren M; Kaya S; Gumus M
J BUON; 2007; 12(4):471-6. PubMed ID: 18067204
[TBL] [Abstract][Full Text] [Related]
6. Docetaxel as second-line chemotherapy for advanced non-small cell lung cancer.
Thongprasert S; Cheewakriangkrai R; Napapan S
J Med Assoc Thai; 2002 Dec; 85(12):1296-300. PubMed ID: 12678167
[TBL] [Abstract][Full Text] [Related]
7. First-line treatment of advanced non-small-cell lung cancer with docetaxel and cisplatin: a multicenter phase II study.
Georgoulias V; Androulakis N; Dimopoulos AM; Kourousis C; Kakolyris S; Papadakis E; Apostolopoulou F; Papadimitriou C; Vossos A; Agelidou M; Heras P; Tzannes S; Vlachonicolis J; Mavromanolakis E; Hatzidaki D
Ann Oncol; 1998 Mar; 9(3):331-4. PubMed ID: 9602269
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II study of paclitaxel plus cisplatin as first-line chemotherapy for advanced non-small cell lung cancer: preliminary results.
Belli L; LeChevalier T; Gottfried M; Adams D; Ruffie P; LeCesne A; Tete L; Pellae-Cosset B
Semin Oncol; 1995 Dec; 22(6 Suppl 15):29-33. PubMed ID: 8643967
[TBL] [Abstract][Full Text] [Related]
9. Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326).
Belani CP; Fossella F
Cancer; 2005 Dec; 104(12):2766-74. PubMed ID: 16288485
[TBL] [Abstract][Full Text] [Related]
10. Overview of docetaxel (Taxotere)/cisplatin combination in non-small cell lung cancer.
Le Chevalier T; BĂ©rille J; Zalcberg JR; Millward MJ; Monnier A; Douillard JY; McKeage MJ; James R; Soulas F; Loret C; Bougon N; Bizzari JP
Semin Oncol; 1999 Jun; 26(3 Suppl 11):13-8. PubMed ID: 10458205
[TBL] [Abstract][Full Text] [Related]
11. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group.
Fossella F; Pereira JR; von Pawel J; Pluzanska A; Gorbounova V; Kaukel E; Mattson KV; Ramlau R; Szczesna A; Fidias P; Millward M; Belani CP
J Clin Oncol; 2003 Aug; 21(16):3016-24. PubMed ID: 12837811
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of epirubicin in combination with weekly docetaxel for patients with advanced NSCLC who have failed or relapsed after the frontline platinum-based chemotherapy.
Lin CM; Chen CH; Chang JW; Tsao TC
Am J Clin Oncol; 2009 Apr; 32(2):169-73. PubMed ID: 19307958
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of paclitaxel and cisplatin in patients with non-small cell lung cancer.
von Pawel J; Wagner H; Niederle N; Heider A; Koschel G; Hecker D; Hanske M
Semin Oncol; 1996 Dec; 23(6 Suppl 16):47-50. PubMed ID: 9007121
[TBL] [Abstract][Full Text] [Related]
14. A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC).
Raez LE; Santos ES; Webb RT; Wade J; Brito RA; Karr M; Kennah A; Childs BH
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1103-10. PubMed ID: 24057043
[TBL] [Abstract][Full Text] [Related]
15. Docetaxel and cisplatin as second-line chemotherapy for advanced non-small cell lung cancer.
Hamada H; Irifune K; Ito R; Sakai K; Kadowaki T; Katayama H; Abe M; Shiode M; Nishimura K; Higaki J
Gan To Kagaku Ryoho; 2007 Aug; 34(8):1235-9. PubMed ID: 17687204
[TBL] [Abstract][Full Text] [Related]
16. A dose escalation study of docetaxel and oxaliplatin combination in patients with metastatic breast and non-small cell lung cancer.
Kouroussis C; Agelaki S; Mavroudis D; Kakolyris S; Androulakis N; Kalbakis K; Souglakos J; Mallas K; Bozionelou V; Pallis A; Adamtziki H; Georgoulias V
Anticancer Res; 2003; 23(1B):785-91. PubMed ID: 12680184
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of weekly docetaxel plus capecitabine for patients with advanced nonsmall cell lung carcinoma.
Han JY; Lee DH; Kim HY; Hong EK; Yoon SM; Chun JH; Lee HG; Lee SY; Shin EH; Lee JS
Cancer; 2003 Nov; 98(9):1918-24. PubMed ID: 14584075
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of docetaxel and carboplatin as second-line treatment in NSCLC.
Wachters FM; van Putten JW; Boezen HM; Groen HJ
Lung Cancer; 2004 Aug; 45(2):255-62. PubMed ID: 15246198
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of combination chemotherapy with docetaxel and carboplatin for elderly patients with advanced non-small cell lung cancer.
Kim HJ; Kim TG; Lee HJ; Kim JH; Lim BH; Seo JW; Kang EM; Lee BU; Ahn YM; Roh YH; Nam SH; Kim BS
Lung Cancer; 2010 May; 68(2):248-52. PubMed ID: 19647333
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of paclitaxel by 96-hour continuous infusion in combination with cisplatin for patients with advanced non-small cell lung cancer.
Breathnach OS; Georgiadis MS; Schuler BS; Pizzella P; Llorens V; Kasturi V; Steinberg SM; O'Neil K; Takimoto CH; Johnson BE
Clin Cancer Res; 2000 Jul; 6(7):2670-6. PubMed ID: 10914708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]